These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38758239)

  • 1. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
    Shimazu Y; Kanda J; Onda Y; Fuchida SI; Ohta K; Shimura Y; Kosugi S; Yamamura R; Matsuda M; Hanamoto H; Adachi Y; Anzai N; Hotta M; Fukushima K; Yagi H; Yoshihara S; Tanaka Y; Takakuwa T; Tanaka H; Shibayama H; Uoshima N; Hosen N; Ito T; Shimazaki C; Matsumura I; Kuroda J; Takaori-Kondo A; Hino M
    Cancer Immunol Immunother; 2024 May; 73(7):135. PubMed ID: 38758239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isatuximab-pomalidomide-dexamethasone
    Richardson PG; Perrot A; Miguel JS; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang SY; Minarik J; Cavo M; Prince HM; Macé S; Zhang R; Dubin F; Morisse MC; Anderson KC
    Haematologica; 2024 Jul; 109(7):2239-2249. PubMed ID: 38299578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
    Decaux O; Fontan J; Perrot A; Karlin L; Touzeau C; Schulmann S; Manier S; Belhadj K; Trebouet A; Zunic P; Schiano De Colella JM; Castel B; Van De Wyngaert Z; Pica GM; Tiab M; Kuhnowski F; Bouketouche M; Rigaudeau S; Benramdane R; Tekle C; Lafore R; Gaucher M; Corre J; Leleu X
    Eur J Haematol; 2024 Sep; 113(3):290-297. PubMed ID: 38712850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
    Dimopoulos MA; Leleu X; Moreau P; Richardson PG; Liberati AM; Harrison SJ; Miles Prince H; Ocio EM; Assadourian S; Campana F; Malinge L; Sémiond D; van de Velde H; Yong K
    Leukemia; 2021 Feb; 35(2):562-572. PubMed ID: 32444867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
    Banerjee R; Lo M; Martin TG
    Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 9. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Dimopoulos M; Bringhen S; Anttila P; Capra M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R
    Blood; 2021 Mar; 137(9):1154-1165. PubMed ID: 33080623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
    Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
    Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
    Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
    Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
    Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab: First Approval.
    Dhillon S
    Drugs; 2020 Jun; 80(9):905-912. PubMed ID: 32347476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
    Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
    Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
    Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
    Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan.
    Tagami N; Uchiyama M; Suzuki K; Shirai H; Seto T; Nishina S; Iida S
    Int J Hematol; 2024 Aug; 120(2):217-228. PubMed ID: 38811413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
    Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
    Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
    Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA
    Future Oncol; 2021 Dec; 17(34):4797-4812. PubMed ID: 34521277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.